Additionally, TLR4 facilitates resistin-triggered ERK activation and NLRP3 upregulation in CRC cells, and inhibiting TLR4 and ERK attenuates these effects, suggesting a potential strategy to enhance the cytotoxic effects of chemotherapy [110]. The gene discussed is NLRP3; the disease is colorectal carcinoma.